Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a solid cancer that started outside the brain (confirmed by lab testing of tissue or cell samples) and who have at least one brain metastasis (cancer that has spread to the brain) that was previously treated with a focused form of radiation called stereotactic radiation.
- People who have a brain lesion (area of abnormal tissue) that has been growing for at least 4 months after stereotactic radiation was delivered to that same spot, and for whom brain surgery to remove the lesion is already planned as part of standard care.
- People aged 18 years or older.
- People who are willing to take part in the study procedures.
- Women who could become pregnant, and men, must agree to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) throughout the study period.
- People who are able to understand the study and are willing to sign a written consent form (either on paper or electronically).
Who may not be able to join:
- People for whom MRI scans are not safe — for example, those with certain metal implants that are incompatible with MRI.
- People with severe or end-stage kidney disease (chronic kidney disease stage 4 or 5, or end-stage renal disease).
- People who have previously had a severe allergic (anaphylactic) reaction to gadolinium, which is a contrast dye used in MRI scans.
- Women who are currently pregnant, as the safety of gadolinium-based contrast agents for a developing baby has not been established.
- Women who are currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ayal Aizer, MD, Brigham and Women's Hospital
Phone: 617-732-7560
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.